chrisvoncsefalvay/vaers-outcomes huggingface dataset:
First dose Pfizer administered 1158. Patient immediately stated she was not feeling well. Patient described tongue and jaw "tingling", lightheadedness, difficulty speaking, and difficulty swallowing. Patient was noted to be slurring her words. Both hands were also noted to be stiffening with patient stating her hands were "numb", unable to grasp writer's hand, with shaking of legs. Epinephrine was administered at 1203. EMS called at 1204. Vitals at 1205: blood pressure 115/71, HR 128. Patient was still in distress - verbalizing difficulty speaking and swallowing, rapid breathing, legs shaking. A second dose of epinephrine was administered at 1209. Vitals at 1210: blood pressure 115/63, HR 133. Pulse ox at 1214 was 100% with HR of 105. At 1216, patient stated her tongue and jaw were still "tingly" but the lightheadedness, hand numbness, and leg shaking had subsided. Vitals blood pressure 109/65, HR 100. 1220: Tongue and jaw tingling "calming down" per patient. 1223: Patient states "everything is back to normal" No tongue swelling or jaw tingling. Vitals: blood pressure 104/60, HR, 95, oxygen 100%. EMS arrived 1252 - vitals blood pressure 102/64, HR 104. EMS asked patient if she wanted to go the ER, patient declined stating that she feels back to baseline except lethargic post epi. Patient had no complaints at this time. Patient was advised to have Benadryl on hand and to follow up with her PCP or go to the ER if any symptoms of a reaction return. Her fiancee states he will be home with her today.
Information has been received from a lawyer concerning her approximately 6 year old grand daughter who on an unspecified date was vaccinated with MMR II (lot number not reported). After getting the vaccination the patient experienced low blood count. Subsequently the patient was admitted in hospital for an unspecified number of days. No further information is available.
Patient had no known side effects; Vaccine Coordinator reported a temperature excursion for VAQTA which was supported. Caller reported that 1 dose of VAQTA was administered to a patient.; This spontaneous report was received from a vaccine coordinator and refers to a patient of unknown age and gender. There was no information about the patient's concurrent conditions, medical history or concomitant therapy provided.  On 04-JAN-2022, the patient was vaccinated with improperly stored 1 dose hepatitis a vaccine, inactivated (VAQTA) prefilled syringe, lot # U024505, expiration date 15-OCT-2022 (exact dose, route of administration and anatomical location were not provided) for prophylaxis (product storage error). It was reported that a temperature excursion for hepatitis a vaccine, inactivated (VAQTA) was supported. No details provided. The patient had no known side effects (no adverse event).
fever, rapid heartbeat, cough, swelling and redness in the area of vaccine, a little rash in the chest, headache. treatment: acetaminophen oral suspension
After having Covid vaccine for 4 days. Hives appear all over my body (chest, back, arms, legs, stomach).
Age 39, MI but post MI recovered fully. Has a stent. Became an ultra-long distance runner, 50-100 miles. Had Moderna 5/13/21 and second shot 18 days later. After 2nd shot, had severe reaction... tremors, fatigue, fever. Thought he had covid and went to urgent care to get tested... negative... no other tests were done. Now has lost all endurance, can only run very short distances with multiple breaks. Weight has increased from 147 to 170lbs. Cardiologist thinks there's a correlation with statins and took him off. See Dr. Cardiac workup negative.  No VAERS report. No cardiac MRI... has a stent so might not be possible. BP has gone up, has had to double lisinopril and start amlodipine.  Has allergies, takes Flonase occasionally. Doesn't irrigate. No snoring. Sleeps well. Has intermittent frontal headaches, exacerbated when sky diving but not air travel. CT scan was negative. Has been diagnosed with reflux laryngitis and takes pantoprazole PRN.
Checked on patient frequently. Patient talking and using her phone 0930, 0935, 0945. Checked on patient again at 0950. She reported a bad headache. Patient reported feeling uneasy at 0955. Called for Medical Response Team. 0956 patient shaky but talking. 0957 patient hooked up to heart monitor. 1004 taken to Emergency Department.
Employee called at 9 am stated she felt lethargic, feverish and her left arm was red & swollen. Complains of severe headache, stated that her eyeballs feel like they there going to pop out of socket. Will refer to PCP for further vaccine recommendations on Hep B & Rabies.
A rash has developed around the body which progressively got worse after the second dose. Rash has continue to spread one week after the second dose.
Rash at injection site; Soreness at injection site; Arm was sore; This is a spontaneous report from a contactable consumer, the patient. A 52-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6207) via an unspecified route of administration in the left arm on 15Mar2021 at 09:45 (at the age of 52-years-old), as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. The patient had no allergies to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 21Mar2021 at 12:00, 6 days after the vaccination, the patient experienced rash and soreness at the injection site. On an unknown date in Mar2021, the patient reported that initially arm was sore for two days, then the patient felt ok until day 6. The patient did not receive any treatment for the events. The events did not result in doctor or other healthcare professional office or clinic visit, and emergency room or department or urgent care. The clinical outcome of the events rash and soreness at the injection site and sore arm were resolved on an unknown date in 2021.   No follow-up attempts are needed. No further information is expected.
Information has been received from a health professional concerning a 47 year old female who on Apr 22 2005 was vaccinated with an intradermal dose of hepatitis B virus vaccine rHBsAg (yeast) (+) Hib conj vaccine (OMPC). It was reported that the patient developed a mark similar to what a positive PPD test looks like but was otherwise asymptomatic. No product quality complaint was involved. Additional information has been requested.
PT noticed significant swelling and inflammation, generalized fevers and achy Sx's. Marked area of cellulitic eruptions surrounding area of Pneumovax on right arm, 'area warm and tender.' Given Rx for Keflex 500 mg tid.
Day 1 child has redness under eyes. Day 2- redness merged and covered nose. Day 3 - hives over body. Day 4- swelling of face - saw Dr. at this time.
Pt states she experienced bouts of lightheadedness and severe chills. Feet became very cold, took warm showers and used heater to stay warm from chills. Reports teeth chattering and night sweats. These effects began approximately 9 days after receiving vaccine. Lasted through Sunday 2/8/15. She stated symptoms were alleviated with ALEVE.
Head ache- started around 1pm on 12/18/20.  Small joint pain started around 7pm on 12/18/20 and continues to present
A report has been received from a Health Professional concerning a 2 year old, Female subject, who had been receiving FLUMIST quadrivalent (intranasal). FLUMIST quadrivalent started on 09-Jan-2015. The reporter stated that expired vaccine was used which started on 09-Jan-2015. FLUMIST quadrivalent was discontinued on 09-Jan-2015. The outcome of the event of administration of expired vaccine is unknown. The report was considered to be non-serious.
Arm of the injection has red spots/blotchy red, not just one dot; 100.2° F; Over 100° F; 99.1° F; No appetite; This spontaneous case was reported by a consumer and describes the occurrence of DECREASED APPETITE (No appetite), RASH MACULAR (Arm of the injection has red spots/blotchy red, not just one dot) and PYREXIA (100.2° F; Over 100° F; 99.1° F) in a 61-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 038K20A) for an unknown indication.     The patient's past medical history included Autoimmune thyroid disorder (may be related to COVID), Premature atrial contraction and COVID-19 in March 2020. Concurrent medical conditions included Drug allergy (some antibiotics). Concomitant products included LEVOTHYROXINE SODIUM (LEVOTHYROXINE [LEVOTHYROXINE SODIUM]) for an unknown indication.    On 25-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 26-Jan-2021, the patient experienced DECREASED APPETITE (No appetite) and PYREXIA (100.2° F; Over 100° F; 99.1° F). On 29-Jan-2021, the patient experienced RASH MACULAR (Arm of the injection has red spots/blotchy red, not just one dot). The patient was treated with PARACETAMOL (TYLENOL) for Fever, at an unspecified dose and frequency. On 28-Jan-2021, DECREASED APPETITE (No appetite) and PYREXIA (100.2° F; Over 100° F; 99.1° F) had resolved. At the time of the report, RASH MACULAR (Arm of the injection has red spots/blotchy red, not just one dot) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.
Hard to breath; Fever; Body ache; Tiredness; This spontaneous case was reported by a non-health professional and describes the occurrence of DYSPNOEA (Hard to breath), PYREXIA (Fever), FATIGUE (Tiredness) and ARTHRALGIA (Body ache) in a 42-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 018B21A and 006C21A) for COVID-19 immunisation.     No Medical History information was reported.   On 01-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 30-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 01-Apr-2021, the patient experienced FATIGUE (Tiredness). On 01-May-2021, the patient experienced DYSPNOEA (Hard to breath), PYREXIA (Fever) and ARTHRALGIA (Body ache). The patient was treated with IBUPROFEN (ADVIL [IBUPROFEN]) at an unspecified dose and frequency. At the time of the report, DYSPNOEA (Hard to breath), PYREXIA (Fever), FATIGUE (Tiredness) and ARTHRALGIA (Body ache) outcome was unknown.            No concomitant medication details was reported.
VACCINE EXPOSURE DURING PREGNANCY; This case was reported by a healthcare professional and described the occurrence of vaccine exposure during pregnancy in a 15-year-old female subject who was vaccinated with tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, adsorbed (Boostrix, GlaxoSmithKline) for prophylaxis while pregnant.  Concurrent vaccination included hepatitis B vaccine (Recombivax, Merck), inactivated poliomyelitis virus vaccine (Sanofi) and seasonal influenza vaccine (Fluzone, Sanofi) given on 15 January 2009. Pervious vaccination included two TD vaccines given in 2005.  On 15 January 2009 at 10:45 the subject received a dose of Boostrix at 0.5 ml in the left arm. This was a case of vaccine exposure during pregnancy. No adverse events were reported.    On 27 January 2009, follow-up information was received from the reporting nurse. The nurse reported that the subject received only immunization series from her Health Department. She reported that she had no way of assessing the information requested on the Pregnancy Initial Notification Form. She tried to call unspecified phone numbers, but no one was available.  Upon internal review done on 13th September 2019, the pregnancy outcome was updated to lost to follow-up.
This literature market report was received from an author. Abstract Studies assessing the economic burden of a mumps outbreak in a highly vaccinated population are limited. A mumps investigation was conducted in an affected village with a highly vaccinated population. To understand the epidemiology, standardized mumps case definition and active surveillance were used to identify mumps cases. In addition, an economic assessment of a combined outbreak investigation and third dose MMR vaccines intervention was performed; estimated by retrospectively evaluating public health response-related activities including use of a third dose of MMR vaccine. From 24-SEP-2009 through 15-JUN-2010, 790 mumps cases were reported-64% were male and highest attack rate was among 11-17 year age group (99.1 cases per 1000 individuals). Of the 658 cases with known vaccination history, 83.6% had documentation of 2 doses of mumps containing vaccine. No deaths were reported. The 2 major exposure settings were schools (71.8%) and households (22.5%). Mumps cases were classified according to the 2008 mumps definition of the Council of Stated and Territorial Epidemiologists (CSTE). A clinical case was defined as an illness with acute onset of the parotitis, lasting at least 2 days, and without other apparent cause. Clinically compatible illness was defined as that which may present as aseptic meningitis, encephalitis, hearing loss, orchitis, oophoritis, parotitis, or other salivary gland swelling, mastitis or pancreatitis. Laboratory confirmation included isolation of mumps virus from clinical specimen, or detection of mumps nucleic acid, or detection of mumps IgM antibody, or demonstration of a 4-fold increase in mumps IgG antibody titer. Mumps cases were then classified epidemiologically. A probable case was defined as that which meets the clinical case definition without laboratory confirmation and was epidemiologically linked to a clinically compatible case. A confirmed case was defined as a case that met the clinical case definition or had clinically compatible illness, and was either laboratory confirmed or was epidemiologically linked to a confirmed case. This report refers to the 2 case-patients with documented 1 doses of Measles, Mumps, and Rubella Virus Vaccine, Live (manufacturer unknown) vaccine, 2 (12%) were found to be mumps IgM antibody positive and on an unknown date the patients developed parotitis. The outcome of event was unknown. The reporter considered events to be related to Measles, Mumps, and Rubella Virus Vaccine, (manufacturer unknown). This is one of the several reports with literature linked. Additional information has been compatible.
Patient fell on another student after feeling faint. Stated he hit his knee. Patient was put in trendelenburger with feet up until less fit. Remined seated for 20 min for observation.
This spontaneous report as received from a nurse refers to an unknown number of patients of unknown age and gender. No information on patients medical history or concurrent conditions was provided. From 16-APR-2015 to 30-APR-2015, the patients were vaccinated with improperly stored RECOMBIVAX HB (dose, route, lot # and expiration date were not provided). The reporting nurse stated she had no researched the medical records, so it was unknown how many patients were involved. The nurse stated no adverse effects were experienced by any patient. This is the one of the several reports from the same reporter's source. Additional information has been requested.
Chills,Body hurt all over, Passed out 3 times, left hand went numb, left arm numb,taken to an urgent care, transferred by ambulance to hospital, MRI, Cat Scan, ECG, neurological determined TIA, mini stroke, spent night in hospital. 4 days later rash on just both arms and both legs. Went to Urgent care directed by Dr put on Pregnazon for 10 days and follow up pack for 5 days.
Headache began 8 hours later. 24 hours after injection 11am on the 23rd) became extremely tired, headache, body aches. After sleeping 4 hours, woke up with fever of 99.9. After 4 more hours, I felt better and had an appetite.
Coughing, fever, headaches. Started showing symptoms around day 4 after exposure to a person with COVID. Symptoms lasted roughly 1 week, although I felt lethargic for about another week afterwards.
a dose of VAQTA that was administered and expired; This spontaneous report was received from an office manager referring to a patient of unknown age and gender. Information about medical history, concurrent conditions and concomitant therapies was not provided.    On 01-DEC-2020, the patient was vaccinated with a dose of expired hepatitis a vaccine, inactivated (VAQTA) (lot # S024396, expiration date 12-OCT-2020, route was not reported) for prophylaxis (expired product administered). The vaccine did not experience any temperature excursions. combinationproductreport: Yes; brandname: VAQTA SYRINGE (DEVICE); commondevicename: Hepatitis A Vaccine, Inactivated; productcode: FMF; devicetype: SYRINGE, PISTON (FMF); devicelotnumber: S024396; expirationdate: 12-OCT-2020; deviceage and unit: 0 ; malfunction: Unknown; deviceusage: Initial; reasonfornoneval: 81 Other; labeledsingleusedevice: No; mdcpreportability: No; mdcpreprationale: Case information does not meet the criteria for Reportability
PT DESCRIBE A RED HARD KNOT AT THE INJECTION SITE AND REDNESS AROUND THE AREA.
4 hours after the Pfizer Vaccine #2, I experienced very strong leg muscle aches.  I took Tylenol and went to sleep.  The muscle aches were gone by 9am the next morning.  Today, 4 days later, I am experiencing  diarrhea and flu-like symptoms (no fever). NOTE:  I did not experience anything but a slight arm muscle ache on the Pfizer Vaccine #1 three weeks prior.
Itching in arms, neck, stomach; Itching at injection site; This spontaneous case was reported by a nurse and describes the occurrence of PRURITUS (Itching in arms, neck, stomach) and VACCINATION SITE PRURITUS (Itching at injection site) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Drug allergy (Anaphylactic reaction to omega 3's in the past). Concomitant products included DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]) for an unknown indication.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PRURITUS (Itching in arms, neck, stomach) and VACCINATION SITE PRURITUS (Itching at injection site). The patient was treated with DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]) for Itching and Vaccination site pruritus, at an unspecified dose and frequency. At the time of the report, PRURITUS (Itching in arms, neck, stomach) and VACCINATION SITE PRURITUS (Itching at injection site) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant products were reported.   Reporter did not allow further contact
Information was received from a pharmacy manager referring to a number of unspecified patients of unknown age and gender. There was no information about the patients' medical history and concurrent condition. On unknown dates, the patients were vaccinated with improperly stored ZOSTAVAX (lot # J014851, expiration date: 24-OCT-2014, first dose on 08-AUG-2014 and last dose on 20-OCT-2014; lot # K010732, expiration date: 31-OCT-2015, first dose on 24-OCT-2014 and last dose on 18-NOV-2014; lot # K012921, expiration date: 29-NOV-2015, first dose on 21-NOV-2014 and last dose on 12-DEC-2014; lot # K015951, expiration date: 23-DEC-2015, first dose on 18-DEC-2014 and last dose on 15-JAN-2015; lot # K019921, expiration date: 24-JAN-2016, first dose on 26-JAN-2015 and last dose on 04-MAR-2015; lot # K021624, expiration date: 07-DEC-2016, first dose on 05-MAR-2015 and last dose on 04-MAY-2015; lot # K024031, expiration date: 20-FEB-2016, first dose on 14-MAY-2015 and last dose on 04-AUG-2015; lot # L011535, expiration date: 03-JUL-2016, first dose on 10-AUG-2015 and last dose on 02-SEP-2015; strength, dose and route unknown). The ZOSTAVAX was stored in a clinic freezer which had operated for 13 months with excursions above 5 degree Fahrenheit for 10-20 minutes three times a day. These temperature variations continued until the problem was discovered on 04-SEP-2015. At that time all ZOSTAVAX was sequestered and new vaccines ordered. This is one of several reports received from the same reporter. Additional information has been requested.
Information has been received from a registered nurse concerning a 6 year old male patient with no known drug reaction/allergies and no pertinent medical history who on 11-APR-2008 was vaccinated with VARIVAX, 0.5 ml, subcutaneously (Lot # 658593/1329U). There was no concomitant medication. The registered nurse reported that on 21-JAN-2009, the patient experienced developed varicella after administration of the vaccine. He had 50 lesions with a majority on his face and neck. At the time of the report, the patient had not recovered. The patient sought medical attention through telephone. Follow-up information was received from the registered nurse indicating that the patient was a white 6 year old male patient, weighing 45 4/3 pounds and 46 inches in height, with no known drug reaction/allergies and no pertinent medical history, who in the afternoon of 11-APR-2008 was vaccinated with the first dose of VARIVAX (Lot # 658593/1329U), subcutaneously in the left leg. There were no illnesses at the time of vaccination. The registered nurse reported that the patient experienced fever 3 days prior to breaking out. The patient presented lesions on mouth, check, nose, neck and trunk. No treatment needed. The patient sought medical attention at the physician's office. At the time of the report, the patient had recovered. No further information is available.
This spontaneous report was received from a registered nurse refers to a 94 year old female patient. The patient's pertinent medical histories, drug reactions/allergies and concomitant medications were not reported. On 19-OCT-2016, the patient was vaccinated with PNEUMOVAX 23 (lot # L033707 and expiry date 18-MAY-2017) intramuscular in the left deltoid. On an unknown date in October 2016, she experienced cellulitis. She was also admitted to hospital for diarrhea. It was not known whether the patient experienced diarrhea before or after. She was discharged from the hospital on 23-OCT-2016. Unspecified treatment was given for the events. The outcome of the event was unknown. The reporter did not provide the relatedness of the events with the vaccine. Upon internal review "cellulitis" was determined to be medically significant. Additional information has been requested.
FOUR HRS AFTER INJECTION PT EXPER PAIN BEHIND EYES, FEVER, OCCIPITAL HEADACHE, GENERAL MALISE, SORE THROAT, FLU LIKE SYMPTOMS AND DEHYDRATION. NO TREATMENT GIVEN. AS OF 02-MAY-90, CYMPTOMS CONTINUED.
Body ache head to toe, temperature 100.9 Friday through Saturday, her normal temp is 97.  She came into the pharmacy today 1/20/2016 at 9:50 am showed me (Pharmacist) her arm, Baseball sized red circle on Right arm on Deltoid, very distinct.  Proper placement for where the vaccine should have been given.  Patient showed her doctor yesterday and doctor was not concerned patient told me.
I had no side effects after the injection except for very slight arm discomfort for a day or two.  Then, the evening of Day 6 (Jan. 20) I felt a little itchy around the injection site.  Morning of Day 7 (Jan. 21) I was very itchy and my upper right arm was very itchy, red and inflamed.   I called my dermatologist, and she told me to use a prescription cream I had from an irritation  on my thumb last year, called Triamcinolone Acetonide Cream 0.1%.   I also called my primary doctor,  to let her know what was happening.  Day 8 (Jan. 22) my upper arm was still very inflamed and seemed to be spreading wider across my arm, maybe 4"x3".  Day 9 (Jan. 23) a little better. Day 10 (Jan. 24) much better. Almost gone. Little bit of red left. Still using cream until it goes away..